NCT04944121View on ClinicalTrials.gov

Phase 2 Study of RSLV-132 in Subjects With Long COVID

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

June 25, 2021

Primary Completion Date

October 31, 2023

Study Completion Date

November 30, 2023

Conditions
Post-acute Corona Virus 19 (COVID-19) (Long COVID)
Interventions
DRUG

RSLV-132

10 mg/kg RSLV-132 administered by intravenous infusion

DRUG

Sodium Chloride 0.9%

0.9% sodium chloride administered by intravenous infusion

Trial Locations (5)

33060

Resolve Clinical Center, Pompano Beach

33134

Resolve Clinical Center, Coral Gables

36608

Resolve Clinical Center, Mobile

37920

Resolve Clinical Center, Knoxville

98103

Resolve Clinical Center, Seattle

Sponsors
All Listed Sponsors
lead

Resolve Therapeutics

INDUSTRY

NCT04944121 - Phase 2 Study of RSLV-132 in Subjects With Long COVID | Biotech Hunter | Biotech Hunter